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Summary: Dynamic interpretation of results is an alternative approach to the conventional cut-off procedure.
Reference change limit is a valuable reference point to interpret dynamically tumour marker values when only
very few serial results can be obtained from a patient after treatment. In this paper, a reference change limit of 2.0
μ§/1 was estimated for carcinoembryonic antigen in patients with complete remission of colorectal cancer. This
figure means that a difference greater than 2.0 μg/l has at least a chance of being statistically significant (at 0.05
probability). As complementary information to the reference change limits, with more than four successive results,
a simple time series model can be used to obtain predictive limits for the next observation.
Introduction
When monitoring cancer patients for possible recurrence
after treatment, it would be helpful to have reference
points derived from the individual patient or, at least,
from a group of patients in remission. A reference point
of the latter type is the "reference change limit" or "criti-
cal difference" to judge the statistical significance of a
change between two successive observations of a tu-
mour marker. The reference change limit is particularly
valuable when only a very few serial values have been
obtained after treatment. When the patient's remission
period has extended long enough to provide a larger
number of observations, predictive limits derived from
a time series model applied to the patient's own record
represent the best reference points-patient-specific val-
ues (1).
There is growing interest in whithin-subject variability.
This information is important in calculating reference
change limits, assessing the appropriateness of conven-
tional reference values, calculating intra-individual ref-
erence values, establishing analytical goals, and helping
in test and specimen selection (2). Most of these studies
have been done in groups of healthy subjects (2—4) al-
though there are some published data on biological vari-
ation in stable patients with chronic disease (5). Inter-
pretation and, consequently, usefulness of tumour
marker results remains controversial (6). At present, ref-
erence points for tumour markers are usually the con-
ventional group-based cut-off points derived from sam-
ples of healthy persons. Several authors have claimed
that a more dynamic approach would be better (7—8).
If criteria were based on relative increase, the interpreta-
tion would improve dramatically (7—18). Therefore, it
would be possible to consider irrelevant increases of dif-
ferences in concentration under the reference change li-
mit, or suspect early recurrence when an increase in con-
centration (not due to biological variation) is detected.
In this paper, we estimate a group-based reference
change limit and patient-specific predictive limits for
carcinoembryonic antigen in patients in remission
following treatment for colorectal carcinoma. These ref-
erence points are then tested against the CEA records of
patients in clinically evident pre-progressive and pro-
gressive stages of the disease, as a preliminary approach.
Materials and Methods
Patients
Patients in complete remission from colorectal cancer following
treatment were selected among patients attending the Hospital de
la Santa Creu i Sant Pau, Barcelona, Spain, during the period Janu-
ary 1990 to December 1992. Selection criteria included:
(a) clinical criteria: minimum of three months since last treatment
(history, examination, every 4 months);
(b) complementary explorations (colonoscopy at 4 and 36 months;
ultrasound and chest X-ray film at 1, 2 and 3 years) (19);
(c) at least four regularly-spaced carcinoembryonic antigen results
(averaging three months apart, but see tab. 1) following treatment
while the patient remained in steady remission.
In order to have a homogeneous group where the only factor under
study was time, patients with benign pathology or presenting
factors able to modify the carcinoembryonic antigen concentration
were excluded. The group numbered 30 patients (20 men and 10
women, aged between 41 and 78 years, stages A (3), B (15), C
(14), D (1), according to the Astler-Coller modified classification
and histology of adenocarcinoma), accounting for 117 successive
observations. At approximately five years after surgery, the patient
records were revised and all remained in remission.
We also selected 17 patients [19 men and 7 women, aged 26-78
years, stages B (4), C (7), D (6)] with colorectal adenocarcinoma
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confirmed clinically or by image exploration (19) after surgical
treatment but in progression or recurrence (20) in order to test how
several calculation approaches to reference changes can modify
the conclusions.
Collection of blood samples and analytical methods
The mean interval between sample collections for each patient was
3.39 months with a range from one to seven months. However,
actual intervals varied considerably, as shown in tables 1 and 2.
Venous blood was obtained by antecubital puncture from seated
subjects and collected directly into plain tubes (10 ml) between
8—10 a.m. with minimal stasis. Serum specimens were obtained
by centrifugation at 10 000 g for 10 minute within one hour after
arrival in the laboratory. Samples were stored at —20 °C until ana-
lyzed, not later than 30 days, and Carcinoembryonic antigen con-
centration was determined by an enzyme-chemiluminometric
method (Amerlite®, Kodak Clinical Diagnostic Ltd., Amersham In-
ternational, Buckinghamshire, UK). This assay involves the simul-
taneous reaction of Carcinoembryonic antigen with sheep poly-
clonal antibodies against Carcinoembryonic antigen-coated wells
and peroxidase-labelled mouse monoclonal antibodies against
Carcinoembryonic antigen. Peroxidase activity is measured by
Tab. 1 Relative frequency distribution (in percent) of the number
of blood specimens obtained (columns labelled 1 to 8) in relation
to the number of months elapsed between consecutive observations
(rows labelled 1 to 7).
Interval
previous
observation
1
2
3
4
5
6
7
Total number
of patients
Number of observations
1
4.0
48.0
24.0
12.0
8.0
4.0
0.0
25
2
20.0
32.0
8.0
24.0
8.0
8.0
0.0
25
3
12.0
24.0
28.0
12.0
12.0
12.0
0.0
25
4
0.0
25.0
15.0
20.0
25.0
5.0
10.0
20
5
0.0
13.3
33.3
40.0
13.3
0.0
0.0
15
6
8.3
16.7
25.0
25.0
16.7
8.3
0.0
12
7
0.0
0.0
25.0
50.0
25.0
0.0
0.0
4
8
0.0
0.0
0.0
100
0.0
0.0
0.0
1
Tab. 2 Relative frequency distribution of months elapsed be-
tween blood specimen collection of all the successive differences
observed, and frequency distribution of the average of time elapsed
(month) per patient.
Interval (in months)
from the previous
1
2
3
4
5
6
7
Total number
of differences
Mean
(standard deviation)
Frequency distribution
of differences observed
All Mean of elapsed
differences time (months)
observed per patient
7.9 0.0
27.6 4.2
21.3 45.8
22.0 29.2
13.4 12.5
5.5 8.3
2.4 4.2
727 25
3.39 (1.14)
enhanced luminescence reaction using a luminol derivative as
substrate.
Three control specimens from Lyphocheck® (Bio-Rad, ECS Divi-
sion, Anaheim, California 92806) and one human serum pool ali-
quot were included in each assay run. Different lots of control
material were used throughout the study period. Coefficients of
variation of the control material assays during this period were:
9.86, 7.17 and 8.55 percent for 3.24, 15.18 and 31.73 μ§/1 respec-
tively (n = 114). Assay procedures remained unchanged through-
out the study period.
Statistical analysis
The primary purpose of this analysis was to determine critical val-
ues (reference change limits) for use in evaluating observed differ-
ences between successive observations early in the monitoring pro-
cess. In addition, we calculated patient-specific predictive limits
after at least four serial observations had been obtained. Because
of the wide variation in sampling intervals and the relatively small
number of patients, the only time series model available to us was
the simple "homeostatic" model (1). This model assumes zero (or
very small) correlation between successive results. A much larger
database (> 300 patients) would have permitted the use of a con-
tinuous autoregressive model allowing for unequal intervals and
stronger serial correlation (21).
These calculations are based on the premise that the patients re-
mained in complete remission during the monitoring period. Under
this hypothesis, both reference change limits and predictive limits
become reference points which, if exceeded, indicate that the pa-
tient may have experienced a recurrence of the disease. In practice
of course, patients may show random deviations beyond these ref-
erence points that prove on further monitoring or other examination
to be false alarms. However, five patients showed consistent up-
ward trends during their first four observations (for example: 0.50,
0.70, 2.10, 2.50 μ^) although none of them ever showed values
over 5 μ^ and some time after they recovered previous values.
These were not considered in calculating the reference change
limit. This reduced the database to 25 patients.
Calculation of Reference Change Limits
We turn now to the determination of a reference change
limit suitable for judging the statistical significance of a
difference between two successive observations. This
will be useful during early monitoring when no more
than 2-4 serial observations have been obtained. The
reference change limit is calculated from the data for
all patients in the group, whereas predictive limits are
calculated for each patient individually.
Calculation of reference change limits was initially pro-
posed by Harris & Brown (4). Since that time, reference
change limits have been computed for many different
analytes, not always using the procedure originally sug-
gested. A discussion of this experience may be found in
Harris & Boyd (22). In brief, this technique involves:
(a) checking the distribution of observed within-person
variances for assumed log-normality;
(b) estimating the mean and standard deviation of these
variances (on the log scale) using Healy's trimming pro-
cedure (23) to obtain robust estimates in the presence
of outliers;
(c) converting these estimates to original scale using
standard formulas [e.g. I.e. (24) and I.e. (4)] testing
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Fig. 1 Distribution of log-variances in a probit scale.
whether observed variances are homogeneous (i.e., esti-
mates of a common true variance). If not, the standard
deviation of true variances is estimated [(24) equation
3]. From this estimate and the estimated mean of true
within-patient variances, the reference change limit is
calculated. Further details and a BASIC program for
these computations are given in Harris & Boyd (22).
First, we examined the distribution of within-person
variances in the 25 patients referred to above. Variances
were computed from all observations of each patient be-
cause as far as is known all patients remained in com-
plete remission during the study period. Two of the 25
patients showed unstable records with unusually large
variances. These were omitted from the reference
change limit calculations. The distribution of the re-
maining 23 variances seemed to be in reasonable agree-
ment with a logNormal form as shown in figure 1, with
the possible exception of the lowest and highest values.
These were (temporarily) deleted for application offfea-
(x's procedure, leaving 21 covariances, based on an
average of 6.0 observations per patient.
The true within-person variances were found to be non-
constant with estimated CV of 99%. Based on the esti-
mated 90th percentile of the distribution of true vari-
ances, a reference change limit of 1.97 μg/l was obtained
and rounded off to 2.00 for convenience1). The inter-
') The BASIC program used here does not allow for varying num-
bers of serial observations per patient. Therefore, as a check on the
reference change limit, we computed the weighted mean and vari-
ance of observed within-patient variances (weighting by the de-
grees of freedom for each patient), omitted Healy's procedure, and
estimated the variance of true variances using the following for-
mula [1. c. (22) p. 196 and 1. c. (25)] that accounts for each patient's
number of observations:
est Var σ? = [var sf - 2 X A X (mean s2)2]
where A is the average value of 1/(η;-1). Then, following the
remaining portion of the program, the calculated reference change
limit came to 1.91 μg/l, in approximate agreement with the value
1.97 computed above. It appears that minor variation in the number
of observations per patient can be safely ignored, substituting the
mean number instead.
pretation of this value is that any difference greater than
2.0 has at least a 90 percent change of being statistically
significant at the 0.05 probability level. Applying this
reference change limit to the 114 successive differences
among the observations in the 23 patients, we found
only one difference (from 5.24 to 2.31 μg/l) that ex-
ceeded this value (which means 0.9 percent of false
alarms or a specificity of 99.1 percent of differences
studied, or 95.6 percent in terms of patients). Of the 12
differences in the two patients with unusually unstable
records, four exceeded this reference change limit. Of
the 50 differences observed hi 17 patients with disease
progression, only two differences were under 2 μg/l (a
sensitivity of 96 percent of differences of 11.8 percent
in terms of patients). In this group, four patients showed
the first observations under the conventional static 5 μg/l
cut-off and two of them showed again a result under
5 μg/l in the second test. However, the difference be-
tween the first and second observations was higher than
the reference change limit in these two cases. Conse-
quently, progression could be suspected 8 and 3 months
respectively before a new assay (the results of which
were respectively 4.7 and 6.5 μg/l) was performed. If,
instead of applying the 90th percentile as the calculation
procedure, we had simply assumed the 23 observed
within-patient variances to be homogeneous and used
their mean (0.2909) as the best estimate of the true vari-
ance, we would have calculated the reference change
limit as 2.77 (0.2909)172, or 1.49 μg/l. This value was
exceeded by 5 of the 114 differences observed among
the 23 individuals (that means 4.4 percent of false
alarms or a specificity of 95.6 percent). There were no
differences in the group of patients with disease pro-
gression. Finally, if, as is commonly done, the median
(0.2274) had been used, the calculated reference change
limit would have been 1.32 μg/l, a value exceeded by 6
of these differences (that means 5.3 percent of false
alarms or a specificity of 94.7 percent). Although the
population of patients with disease progression is lim-
ited to have a good sensitivity estimation, the better
specificity is obtained with a reference change limit cal-
culated as proposed originally (22).
The five patients provisionally excluded from the calcu-
lations showed a mean of a intra-individual variances of
0.40. The highest of the 27 differences observed in the
patients of this group was 1.40 (from 0.70 to 2.10 μg/l).
The inclusion of this group would slightly modify the
reference change limit from 1.97 to 2.07 μg/l.
Individual Predictive Limits
After four successive results at approximately equal time
intervals have been obtained, the reference change limit
may be replaced, or at least supplemented, by a simple
time series model used sequentially to obtain predictive
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limits for future observations in the individual patient.
Details of this methodology, and relevant references,
appear in Harris & Boyd (22). Briefly, given four serial
observations, not necessarily equally spaced, while the
patient remains in steady state, and assuming zero (or
very small) serial correlation, the best estimate for the
fifth observation is the mean of the first four, with 95
percent predictive range given by this mean ± "t"0 025, 2
s4 (5/4)1/2, where "t"9.925,2 denotes the two-sided value
of Student's t at two degrees of freedom and the 0.05
probability level. In general, provided the patient re-
mains in steady state, and the serial correlation of suc-
cessive observations remains very low, the best predic-
tor of the t-th observation, based on (t-1) observed val-
ues, and associated 95 percent predictive range is
given by:
xt-i ± 0.025, (t (Eq. 1)
Where xt_i and st_! are the mean and standard deviation,
respectively, of the first (t-1) observations. Since only
higher than usual observations are of clinical importance
in this application, only the upper predictive limit should
be computed and a one-sided value of "t" used to
increase sensitivity.
Including all patients with at least five serial observa-
tions, but excluding those showing a significant trend in
the first four observations, 20 patients remained. For
each of these patients, equation 1 was used to calculate
upper predictive limits for the fifth and later observa-
tions. Of the 56 observations tested, only 4 exceeded
their respective upper predictive limits: 1.19 μg/l for a
predictive interval of (0.35-0.68 μg/l); 1.97 (1.0-
1.79); 1.09 (0.12-0.90) and 1.8 (0.1-1.25). Therefore,
the rate of false positive signals is 7 percent. None of
the 5 cases excluded from the reference limit change
calculation exceeded their respective upper predictive
limit.
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